Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1231 to 1245 of 2208 results for guidelines

  1. ColonFlag for identifying people at risk of colorectal cancer (MIB142)

    NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .

    Medtech innovation briefing
    Published
    12 April 2018

  2. Bimekizumab for treating moderate to severe plaque psoriasis (TA723)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    1 September 2021
    View recommendations

    Sections for TA723

  3. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA418

  4. Prostate-specific antigen testing: What is the diagnostic accuracy of using age-adjusted and fixed prostate-specific antigen thresholds for people with symptoms of prostate cancer, including those at high risk of developing prostate cancer (such as those with an African family background or a family history of prostate cancer)?

    population that had already been referred to secondary care. The 2019 guideline recommended referral if PSA levels were above the...

    Research recommendation
    Published
    7 January 2022

  5. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

    Medtech innovation briefing
    Published
    8 April 2020

  6. What is the natural history of post-COVID-19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  7. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (HTG316)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.

    HealthTech guidance
    Published
    14 August 2013
    View recommendations

    Sections for HTG316

  8. Evidence summaries: new medicines – Interim process statement (PMG1)

    This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs

  9. What symptoms do children, young people, pregnant women and older people with suspected post‑COVID‑19 syndrome present with?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  10. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    12 July 2017
    View recommendations

    Sections for TA456

  11. What is the clinical effectiveness of D-dimer and other blood tests and clinical features as prognostic markers of developing post‑COVID‑19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  12. Low dose rate brachytherapy for localised prostate cancer (IPG132)

    Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.

    Interventional procedures guidance
    Published
    27 July 2005
    View recommendations

    Sections for IPG132

  13. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  14. Radiation-induced lymphopenia and risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose patients to an increased risk of new COVID-19 and does it contribute to patients developing more severe COVID-19?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021

  15. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA895